Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis

R Olsson, I Hägerstrand, U Broomé, Å Danielsson, G Järnerot, L Lööf, H Prytz, B-O Rydén, S Wallerstedt

Abstract

Aims—To study sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis (PSC).

Methods—One hundred and twelve biopsy specimens (that is, 56 pairs) from 44 patients with PSC, confirmed by cholangiography, were evaluated blindly. Six different features, qualitative grading of four other features and staging according to Ludwig were assessed.

Results—Quantitative sampling variability was confined mainly to just one grade or stage, although 11% (six of 56) of the biopsy specimen pairs differed by more than one stage (7% (one of 15) in pairs >2 cm in length). Qualitative sampling variabilities were between 18 and 71%. Advanced disease (stages 3 or 4) was missed in 40% (two of five) of the biopsy specimens while cirrhosis was missed in 37%.

Conclusions—Percutaneous liver biopsy specimens should be taken in clinical studies of PSC using liver histology for evaluation or prognosis.

(J Clin Pathol 1995;48:933–935)

Keywords: Sampling variability, primary sclerosing cholangitis.

Liver biopsy is essential for the diagnosis and control of liver disease. The risk of sampling error has been evaluated in both postmortem studies and in living patients.1–4 There is general agreement that liver biopsy is an accurate method for diagnosing diffuse changes in the liver, such as fatty infiltration, acute and chronic hepatitis and venous congestion. There is considerable sampling error, however, in macro- and micronodular cirrhosis, although less so in micronodular cirrhosis. None of the reports published on sampling variability have dealt with primary sclerosing cholangitis (PSC). The aim of the present study was to evaluate sampling variability as a part of a double blind, multicentre study of the use of colchicine in the treatment of this disease, reported elsewhere.5

Methods

The investigation was performed by members of the Swedish Internal Medicine Liver Club (SILK). Percutaneous liver biopsy specimens were obtained, using a Menghini needle (1.4 to 1.6 mm in diameter), from 44 patients with PSC, 30 of whom had inflammatory bowel disease, before and/or after three years of treatment with colchicine or placebo. The diagnosis of PSC was confirmed by cholangiography. The clinical trial included 84 patients and although we intended to take two specimens at each biopsy, this was possible on only 56 occasions giving 112 specimens in total. The main constraint was concern about complications. The biopsies were performed by different physicians—that is, not only by the principal investigator at each centre. During the biopsy procedure, the needle was introduced twice in different directions through the same puncture.

The liver biopsy specimens were fixed in 4% formaldehyde and embedded in paraffin wax. Several sections were cut and stained with haematoxylin and eosin, periodic acid Schiff, with and without diastase treatment, and for collagen, iron, bile, and reticulin. The slides were assessed blindly by one of the authors (IH).

The following characteristics were graded on a scale from 0 (normal) to 3 (severe): portal lymphocytic infiltration, portal fibrosis, bile duct and ductal proliferation, steatosis, cholestasis, and septal fibrosis—that is, septa of different lengths extending from the portal zone into the lobule and not necessarily porto-portal.

The following characteristics were noted as being present or absent: portal granuloma, periductal fibrosis, cirrhosis, and bile duct destruction—that is, inflammation, proliferation, atypia, necrosis, or atrophy of the duct epithelium. Each biopsy specimen was classified into one of five stages (including normal liver) according to Ludwig.6 With respect to the stage 3 classification according to Ludwig the hallmark of stage 3 is the presence of porto-portal septa. In our opinion, however, such septa may occur even without portal fibrosis, the hallmark of stage 2 disease. In the present study, patients were only classified as having stage 3 disease when porto-portal septa were present together with portal fibrosis. A paucity of bile ducts and lobular change, including piecemeal necrosis, were only encountered occasionally and were not recorded.

In total, 112 biopsy specimens (56 pairs) from 44 patients were evaluated. Paired biopsy specimens from both the beginning and end of the three year treatment period were available for 12 patients.

Sampling variability was calculated in two ways: (1) qualitative analysis—that is, the percentage of biopsy specimen pairs showing disagreement with regard to a particular feature; and (2) quantitative analysis—that is, the percentage of biopsy pairs showing disagreement with regard to a feature on the scale from 0 to

Medical Clinic, Sahlgrenska Hospital, Göteborg R Olsson
Medical Clinic, Östra Hospital, Göteborg S Wallerstedt
Medical Clinic, Huddinge Hospital, Stockholm U Broomé
Medical Clinic, University Hospital, Umeå A Danielsson
Medical Clinic, Regional Hospital, Örebro G Järnerot
Medical Clinic, University Hospital, Uppsala L Lööf
Medical Clinic, University Hospital, Lund H Prytz
Medical Clinic, University Hospital, Linköping B-O Rydén
Department of Pathology, Lund Infirmary, Lund I Hägerstrand

Correspondence to: Dr R Olsson, Medical Clinic, Sahlgrenska sjukhuset, S-413 45 Göteborg, Sweden.
Accepted for publication 9 March 1995

933
Table 1. Results of qualitative analysis of liver biopsy sampling variability in PSC, showing the number of biopsy pairs with a diagnostic feature in only one biopsy sample, out of the total number of biopsy pairs with the feature in at least one of the liver biopsy samples. The results for these 15 pairs of biopsy samples in which both samples were ≥2 cm in length are also given.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Total no. of biopsy specimen pairs (n=56)</th>
<th>Disagreement</th>
<th>Both biopsy specimens ≥2 cm (n=15)</th>
<th>Disagreement</th>
<th>Overall occurrence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal lymphocyte infiltration</td>
<td>11/44 (25%)</td>
<td>3/12 (25%)</td>
<td>66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portal fibrosis</td>
<td>10/50 (20%)</td>
<td>5/12 (42%)</td>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Septal fibrosis</td>
<td>7/39 (18%)</td>
<td>1/8 (23%)</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile duct proliferation</td>
<td>8/24 (34%)</td>
<td>1/4 (25%)</td>
<td>36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steatosis</td>
<td>2/8 (25%)</td>
<td>1/3</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholestasis</td>
<td>4/6 (67%)</td>
<td>0/0</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>3/8 (37%)</td>
<td>0/1</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile duct destruction</td>
<td>5/7 (71%)</td>
<td>2/3</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Periductal fibrosis</td>
<td>3/6 (50%)</td>
<td>1/2</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granuloma</td>
<td>1/2 (50%)</td>
<td>0/1</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Results of the quantitative analysis of liver biopsy sampling variability in PSC, showing the percentage of biopsy pairs differing a scale from 0 to 3. For all features without stages, the feature was classified on a scale from 0 to 3 and for stages on a scale from 0 to 4. The results for the 15 pairs of biopsy samples ≥2 cm in length are also given.

<table>
<thead>
<tr>
<th>Disagreement (grade)</th>
<th>Total (n=56)</th>
<th>Both biopsy specimens ≥2 cm (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 1 2 3 4</td>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>Portal lymphocyte infiltration</td>
<td>68 29 3 0 0</td>
<td>66 33 0 0 0</td>
</tr>
<tr>
<td>Portal fibrosis</td>
<td>63 34 2 2</td>
<td>66 33 0 0 0</td>
</tr>
<tr>
<td>Periportal fibrosis</td>
<td>71 27 2 0</td>
<td>87 13 0 0 0</td>
</tr>
<tr>
<td>Bile duct proliferation</td>
<td>80 14 6 0</td>
<td>87 13 0 0 0</td>
</tr>
<tr>
<td>Cholestasis</td>
<td>93 7 0 0 0</td>
<td>100</td>
</tr>
<tr>
<td>Steatosis</td>
<td>96 4 0 0 0</td>
<td>93 7 0 0 0</td>
</tr>
<tr>
<td>Stage</td>
<td>73 16 9 2 0</td>
<td>60 33 7 0 0</td>
</tr>
</tbody>
</table>

3. This analysis was restricted to staging and to the six features subjected to grading (see above).

Results

Of the 112 biopsy specimens, 47 were ≥2 cm in length. For 15 pairs, both biopsy samples were ≥2 cm in length. On histology, 10 patients had stage 0, eight stage 1, 18 stage 2, 13 stage 3, and seven stage 4 disease.

The results are summarised in tables 1 and 2. The overall occurrence of the 10 histological features in the 112 biopsy specimens is also shown in table 1. The different features evaluated in the biopsy specimens showed qualitative sampling variabilities of between 18 and 71%. There was no consistent improvement in sampling variability in the subsample of biopsy specimens in which both samples were ≥2 cm in length. Quantitative sampling variability was confined mainly to just a single grade or stage. However, 11% (six of 56) of the biopsy specimen pairs differed by more than one stage. This figure was reduced to 7% (one of 15) when both samples were ≥2 cm in length. Advanced disease (stages 3 or 4) was diagnosed in 22 patients. In six (27%) of these, one biopsy specimen in the pair was classified as stage 0, 1 or 2. When the analysis was restricted to the 15 pairs in which both biopsy specimens were ≥2 cm in length, advanced disease was missed in 40% (two of five) of patients.

Discussion

Portal fibrosis and portal lymphocytic infiltration were the most common histological features noted (table 1), which is consistent with the early evolution of the disease. From a diagnostic point of view, the most important histological abnormalities are bile duct destruction and periductal fibrosis. These abnormalities were observed in only 8% of the biopsy specimens, a figure considerably lower than that recorded in previous reports.8 11 This anomaly may have come about because more patients in this study had stage 0 to 2 disease. The most common pathological finding was thin, non-bridging, periolobular, fibrous septa. The lack of diagnostic changes emphasises that the diagnosis of PSC must be based on the characteristic cholangiographic manifestations of the condition and not on histology. Nevertheless, liver biopsy is recommended in PSC as a prognostic feature in survival models.13 In view of this, determination of the sampling variability in liver biopsy is essential.
It should be pointed out, however, that the present study does not provide any information on the sensitivity of needle biopsy for detecting different histological features in PSC— that is, the probability of detecting each of the different histological features of the disease in a single biopsy specimen. Such a study would have required a comparison of needle biopsy samples with considerably larger liver samples obtained, for example, at necropsy. Our data show, however, that there is at least a 20% risk of missing important features on blind needle biopsy (table 1). Sensitivity was not improved when the length of both biopsy samples was at least 2 cm. Cirrhosis was consistently diagnosed in only 63% of paired biopsy specimens. Thus, examination of a single biopsy specimen could result in this diagnosis being missed in 37% of patients. Similar variability has been found in various types of cirrhosis. As anticipated, the sampling variability of a feature was related to the overall occurrence of this feature (figure), thus steatosis, cholestasis and bile duct destruction appear as outliers. As no sampling variability was reported for steatosis in a previous series of 25 patients, our figure of 25% is unexpectedly high. The high sampling variability for bile duct destruction (71%) is notable as this is considered to be of high diagnostic value in PSC.

Quantitative analysis of liver biopsy sampling variability revealed minor disagreements (table 2). The most marked disagreements concerned staging; only 73% had no disagreement at all and 11% disagreed by more than one stage. Correlation between specimens in the subset in which both biopsy specimens were >2 cm in length was no better, possibly because of the limited amount of material available. The relatively high sampling error of the staging procedure can be explained by the sampling variability of the different features that characterise staging, none of which have a sampling variability below 18% (table 1).

In many clinical studies patients are either described as having early (stages 1 or 2) or advanced (stages 3 or 4) disease. The present study demonstrates that there is a considerable risk (40%) of missing advanced disease on examination of a single liver biopsy specimen, even if it is >2 cm in length. This high figure was observed when biopsy specimens obtained on multiple passes at the same percutaneous site were compared. Had the study compared samples obtained from—for example, the right and left lobes of the liver, the difference would perhaps have been even greater.

We know from clinical experience that the different biochemical variables used in survival models show marked variations during the course of PSC. This study has demonstrated that the histological staging of needle biopsy specimens is also impaired by the considerable variation in the expression and severity of the disease in different parts of the liver. Paired biopsy specimens are recommended in studies using prognostic indexes including the histological stage and in those evaluating the results of therapeutic intervention.

The authors gratefully acknowledge the financial support of G.D. Searle Ltd.
Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis.

R Olsson, I Hägerstrand, U Broomé, A Danielsson, G Järnerot, L Lööf, H Prytz, B O Rydén and S Wallerstedt

doi: 10.1136/jcp.48.10.933

Updated information and services can be found at:
http://jcp.bmj.com/content/48/10/933

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/